Alpha-actnin-4 (ACTN4) selectively affects the DNA double-strand breaks repair in non-small lung carcinoma cells.

Abstract

BACKGROUND:

ACTN4 is an actin-binding protein involved in many cellular processes, including cancer development. High ACTN4 expression is often associated with a poor prognosis. However, it has been identified as a positive marker for platinum-based adjuvant chemotherapy for non-small cell lung cancer (NSCLC). The goal of our study was to investigate the involvement of ACTN4 in the NSCLC cells' response to the genotoxic drugs.

RESULTS:

We generated H1299 cells with the ACTN4 gene knock-out (ACTN4 KO), using the CRISPR/Cas9 system. The resistance of the cells to the cisplatin and etoposide was analyzed with the MTT assay. We were also able to estimate the efficiency of DNA repair through the DNA comet assay and gamma-H2AX staining. Possible ACTN4 effects on the non-homologous end joining (NHEJ) and homologous recombination (HR) were investigated using pathway-specific reporter plasmids and through the immunostaining of the key proteins. We found that the H1299 cells with the ACTN4 gene knock-out did not show cisplatin-resistance, but did display a higher resistance to the topoisomerase II inhibitors etoposide and doxorubicin, suggesting that ACTN4 might be somehow involved in the repair of DNA strand breaks. Indeed, the H1299 ACTN4 KO cells repaired etoposide- and doxorubicin-induced DNA breaks more effectively than the control cells. Moreover, the ACTN4 gene knock-out enhanced NHEJ and suppressed HR efficiency. Supporting the data, the depletion of ACTN4 resulted in the faster assembly of the 53BP1 foci with a lower number of the phospho-BRCA1 foci after the etoposide treatment.

CONCLUSIONS:

Thus, we are the first to demonstrate that ACTN4 may influence the resistance of cancer cells to the topoisomerase II inhibitors, and affect the efficiency of the DNA double strand breaks repair. We hypothesize that ACTN4 interferes with the assembly of the NHEJ and HR complexes, and hence regulates balance between these DNA repair pathways.

• Authors: Daria Kriger, Ksenia Novitskaya, Giomar Vasileva, Ekaterina Lomert, Nikolai D Aksenov, Nikolai A Barlev, Dmitri Tentler
• Journal: Biology direct (Biol Direct) Vol. 17 Issue 1 Pg. 40 (12 07 2022) ISSN: 1745-6150 [Electronic] England
• PMID: 36476259 (Publication Type: Journal Article)
• Copyright: © 2022. The Author(s).

Chemical References

• Topoisomerase II Inhibitors
• Doxorubicin
• ACTN4 protein, human
• Actinin

Topics

• Humans
• Lung Neoplasms (genetics)
• Carcinoma, Non-Small-Cell Lung (genetics)
• Topoisomerase II Inhibitors
• Doxorubicin
• Carcinoma
• Lung
• Actinin